Detailed Narrative
Overall Performance & Strategic Diversification
Laurus Labs reported a strong Q4 FY25 with total income from operations reaching ₹1,720 crores, marking a 19% YoY growth. For the full fiscal year, revenue stood at ₹5,554 crores, a 10% increase from the previous year. The company's strategic diversification efforts have reduced ARV revenues' share from 67% to 45% over the last five years, while CDMO's share has grown from 13% to 28%. This shift is supported by continued transformative progress in enhancing capabilities and capacities, meeting complex customer needs.
CDMO Business Growth
The CDMO segment demonstrated robust performance, with the small molecule division recording Q4 sales of ₹461 crores and achieving 49% growth for FY25. This growth was driven by mid-to-late-stage NCE deliveries and increased sales from new manufacturing assets. The CDMO pipeline remains healthy with over 110 active projects, including 90 in human health and 20 in animal health/crop sciences. The company is investing ₹250 crores in a fermentation facility in Vizag, aiming to more than double its capacity by end of 2026, and plans to invest over $15 million in a GMP facility for gene therapy and antibody drug conjugates.
Generics & FDF Performance
The generics division, encompassing ARV and developed market portfolios, reported Q4 sales of ₹1,230 crores. The FDF division grew 25% for the quarter and 12% for the full year, with increased sales expected in future quarters due to executed integrated CMO contracts. ARV sales for FY25 were maintained at around ₹2,550 crores, with Q4 ARV sales at ₹800 crores, split approximately 50/50 between API and formulations. The company expects ARV sales to remain in the ₹2,400-2,600 crore range for FY26.
ImmunoACT & Gene Therapy Initiatives
Laurus Labs' associate company, ImmunoACT, has successfully supported approximately 300 patients with NexCAR19 and completed Phase I trials for pediatric use. Additional manufacturing capacity for NexCAR19, aiming for 2,500 treatments annually, is on schedule to be operational by September 2025. The company has also recruited new leadership for gene therapy and antibody drug conjugates, planning a $15 million investment in a GMP facility for these capabilities.
Capital Expenditure & Debt Management
Capital expenditure for Q4 FY25 was ₹211 crores, bringing the full-year total to ₹659 crores, primarily directed towards CDMO and CMO projects. The company anticipates approximately ₹1,000 crores in capex for FY26, including investments in formulation CMO, fermentation capacity, and new production blocks. Net debt stood at ₹2,594 crores, with a net debt to EBITDA ratio of 2.3, down from 3.1 in the previous year. Management expects debt levels to remain stable, with no significant increase to fund future capex.
R&D and Quality Focus
R&D expenditure for FY25 was 4.5% of sales, a 7% increase YoY, reflecting the company's focus on advanced technologies like biocatalysis, flow chemistry, and high-energy chemistry. Laurus Labs underwent nearly 160 quality audits by regulatory agencies and customers in 2025, completing them without critical findings and receiving EIR for Unit 4. The company emphasizes strengthening its project funnel and servicing early-stage clinical programs through its new small-molecule R&D facility.
Outlook and Margin Improvement
Laurus Labs projects significant growth in revenues and profits for FY26, with operating margins expected to improve due to better asset utilization and a favorable product mix. The company's strategy involves deepening collaboration with major clients and executing on CDMO potential. As the CDMO share of revenue increases, management anticipates a corresponding improvement in overall margins, reinforcing confidence in the company's long-term growth trajectory.